Welchol Logo - Two goals, one therapy

Efficacy of Welchol

Sign Up for Updates

Be notified about site updates, educational opportunities, and more.

Two Goals, One Therapy

Welchol is the first and only therapy approved as an adjunct to diet and exercise, to reduce both A1C and LDL-C for adult patients with type 2 diabetes and/or primary hyperlipidemia. Make Welchol your first-choice add-on therapy to help them achieve their goals.

The American Diabetes Association (ADA) and the American College of Cardiology (ACC) emphasize that it is critical to reduce both A1C and LDL-C in patients with type 2 diabetes.1-4

  • Nearly 40% of adults with T2DM also have elevated LDL-C5
  • Patients with T2DM have a CVD risk equivalent to that of a post-MI patient6

Welchol offers a unique combination of benefits.

Welchol delivers efficacy without being systematically absorbed.

Efficacy in Type 2 Diabetes

Adding Welchol to a sulfonylurea, metformin or insulin significantly improved glycemic control

Efficacy in Primary Hyperlipidemia

Make Welchol the preferred partner to a statin


Please see Important Safety Information about Welchol below

Welchol On Demand

Access recent Webcasts from leading physicians

Important Safety Information
Important Safety Information

References

1. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168(18):1975-1983.

2. Welchol (colesevelam HCI). Prescribing Information. Daiichi Sankyo, Inc., Parsippany, NJ, 2009.

3. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-822.

4. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-126. http://circ.ahajournals.org/cgi/content/full/115/1/114. Accessed April 26, 2010.

5. 2004 National Healthcare Quality Report (NHQR). US Dept. of Health and Human Services. March 2005. AHRQ Publication No. 05 0013.

6. US Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report. September, 2002. NIH Publication No. 02-5215. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed April 26, 2010.

This information is intended for U.S. healthcare professionals only.
© 2010 Daiichi Sankyo, Inc.